News | October 20, 2022
Lupin to acquire two inhalation brands from Sunovion for US$75 million
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
Subscribe To Our Newsletter & Stay Updated
